Tag: Teva
MedinCell – Partner Teva provides 2024 sales forecast for UZEDY™ and provides update on long-acting injectable olanzapine treatment candidate – 01/31/2024 at 10:00 p.m.
· UZEDY revenue forecast for Teva in 2024: ~$80 million · Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection…
MedinCell – Partner Teva announces the end of patient recruitment in the phase 3 clinical study of mdc-TJK, long-acting injectable treatment of olanzapine – 01/09/2024 at 7:20 p.m.
Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the…
Sanofi: collaboration with Teva in the treatment of inflammatory bowel diseases
(AOF) – Sanofi and Teva Pharmaceuticals, American subsidiary of Teva Pharmaceutical Industries Ltd. have entered into a collaboration for the co-development and co-commercialization of TEV’574, an asset currently undergoing phase…
Sanofi: alliance with Teva in two intestinal diseases
(CercleFinance.com) – Sanofi announces a collaboration with Teva to co-develop and co-market TEV’574, currently in phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two inflammatory…
MedinCell: first positive feedback from Teva in the USA
(CercleFinance.com) – MedinCell stock rose on the Paris Stock Exchange on Thursday following the announcement by its partner Teva of the successful launch in the United States of a treatment…
MedinCell Partner Teva Announces Successful Launch of UZEDY™ – 2023-08-02 22:52
MedinCell Partner Teva Announces Successful Launch of UZEDY™ Euronext: MEDCL – Montpellier – France – August 2, 2023 – 10:00 p.m. ________________________________________________________________________________ Richard Francis, Chairman and Chief Executive Officer of…
MedinCell partner Teva confirms expecting US approval and commercialization of mdc-IRM/TEV46000 in the first half of 2023 – 07/27/2022 at 20:00
Kåre Schultz, Chairman and CEO of Teva, spoke today during the presentation of the results for the second quarter of 2022. Responding to questions from attendees, Schultz said, “We are…
MedinCell: Teva Provides Additional Information for mdc-IRM Approval Application
By Alexandra Saintpierre Published on 05/03/2022 at 9:54 p.m. Photo credit © Reuters …
Teva, partner of MedinCell, provides additional information regarding the application for approval of mdc-IRM – 05/03/2022 at 21:00
Kåre Schultz, Chairman and Chief Executive Officer of Teva, spoke today during the presentation of the results for the first quarter of 2022. He provided information following the recent receipt…
MedinCell SA: Teva and MedinCell received full response letter for TV-46000/mdc-IRM
PARSIPPANY, NJ, TEL AVIV & PARIS – Teva Pharmaceuticals, American subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) today announce that the U.S. Food…
Teva and MedinCell have received a complete response letter for TV-46000/mdc-IRM – 04/19/2022 at 23:15
PARSIPPANY, NJ, TEL AVIV & PARIS – Teva Pharmaceuticals, US subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) today announce that the U.S. Food…
Teva devotes a documentary to the difficulties of obese women at work
Heloise Goy with Gauthier Delomez 11:46 a.m., March 04, 2022modified to 12:06 p.m., March 04, 2022 INTERVIEW Teva takes up a delicate subject on Friday evening. The M6 group channel…